Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

This study found that Trichoscope can effectively reveal clinical features of alopecia areata and androgenic alopecia, making it a useful tool for diagnosis and monitoring.

This narrative review reflects on the challenges faced by FDA's Oncologic Drugs Advisory Committee members, highlighting public pressure, decision-making complexity, and the evolving landscape of cancer drug development.

This study found that videodermoscopy reveals distinct dermoscopic features in patients with alopecia areata incognita, aiding in biopsy decisions by identifying the appropriate sampling area and potentially avoiding unnecessary procedures.

In this study, optical coherence tomography detected hair follicles at the dermoepidermal junction not visible on the scalp surface in alopecia areata patients, suggesting OCT may help monitor treatment response.

This study identified a novel microscopic "arrow sign" in hair root sheaths of patients on EGFR inhibitors, potentially aiding in diagnosing related hair changes and differentiating from fungal infections.

This study found that WD-aptamer increased β-catenin expression and promoted human hair follicle dermal papilla cell proliferation by interfering with the CXXC5-Dvl1 interaction in the Wnt signaling pathway.

Genetic testing for hairless gene mutations is crucial to correctly diagnose and treat atrichia with papular lesions.

This study reported that atypical variants of alopecia areata made up less than 25% of all cases in their specialized trichology unit, suggesting a potential selection bias.

This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.

This study reported that oral JAK inhibitors, tofacitinib and ruxolitinib, may effectively promote hair regrowth in alopecia areata patients, though ruxolitinib had fewer adverse events compared to tofacitinib.

This study suggests that Ptprq in the hair bundles may exist as multiple isoforms that are differentially expressed throughout development and affect the organization of stereocilia in the chick inner ear.

This study found that Atractylodes macrocephala Koidz. extract promotes anagen entry and hair regrowth by enhancing dermal papilla cell activity and supporting hair cycle progression in a mouse model.

This study found that baricitinib, a Janus kinase inhibitor, was more effective than traditional treatments for severe alopecia areata, with higher rates of significant hair regrowth after 6 months, despite mild-to-moderate side effects and some instances of weight gain.

This study demonstrates the use of rPanglaoDB, an R package for combining public single-cell datasets, to create the first unbiased transcriptome profile of fibrocytes, revealing their role in tissue healing.

This study found that a bioorthogonal microneedle patch delivering AAV-aFGF effectively improved hair follicle regeneration and sustained hair growth in murine alopecia models compared to other methods.

KAP genes are crucial for hair development and show both shared and unique traits in humans, chimpanzees, and baboons.

In this study, researchers discovered a dominant variant in the ADAM17 gene that causes hypotrichosis with woolly hair, where the mutation leads to hair follicle stem cell exhaustion and abnormal hair follicles, resulting in alopecia.

This case study reports that a heterozygous missense GJA1 mutation, p.Gly138Ser, in a 2-year-old boy with oculodentodigital syndrome primarily resulted in syndactyly, fifth finger hypoplasia, and hypotrichosis, without neurological or craniofacial abnormalities.

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

This index reviews the clinical examination of farm animals and reports no new research findings.

This review discusses the FDA-approved JAK inhibitor baricitinib as a treatment for alopecia areata, highlighting its dosing regimen, clinical challenges, and the need for additional safety data while exploring the potential of other topical and sublingual JAK inhibitors under investigation.

This study identified 53 keratins in the yak genome, predicting diverse phosphorylation sites and subcellular localizations, and highlighted strong gene expression correlations during the yak hair follicle development cycle.

The document's conclusion cannot be determined because the content is not available.

This study developed a transgenic mouse model to explore androgenetic alopecia, finding that inducible COX2 expression led to sebaceous gland changes and hair miniaturization, with reversible effects upon reducing COX2.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study found that polymorphisms in the KAP8.1 gene were significantly associated with cashmere weight, length, and guard hair length in Chinese Inner Mongolian Cashmere goats, but not with fibre diameter.